Clinical applications of monoclonal antibodies in gynecologic oncology

Lloyd H Smith, N. N H Teng

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The advances of both murine and human monoclonal antibody (MoAb) technology have allowed the development of several antibodies against gynecologic tumors. The goals are to produce effective and specific reagents for both immunodiagnosis and therapy. However, despite an extensive research effort, a clear demonstration of specific cancer-associated antigens in gynecologic malignancies, or of specific immune responses to such antigens has been elusive. Currently, most antibodies found are cross reactive with either oncofetal antigens or some normal adult tissues. Clinical usefulness of these MoAbs as a screening test in radioimaging or in immunotherapy remains to be proven. However, the use of MoAb technology is defined antigens/tumor markers such as beta-human chorionic gonadotropin, and alpha fetal proteins has provided convenient, reproducible and highly specific reagents. More recently, promising antibodies have been shown to detect tumor antigens in serum of patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)2068-2074
Number of pages7
JournalCancer
Volume60
Issue number8 SUPPl.
StatePublished - 1987
Externally publishedYes

Fingerprint

Monoclonal Antibodies
Antigens
Antibodies
Fetal Proteins
Technology
Neoplasms
Immunologic Tests
Neoplasm Antigens
Chorionic Gonadotropin
Tumor Biomarkers
Ovarian Neoplasms
Immunotherapy
Serum
Research
Therapeutics
oncofetal antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical applications of monoclonal antibodies in gynecologic oncology. / Smith, Lloyd H; Teng, N. N H.

In: Cancer, Vol. 60, No. 8 SUPPl., 1987, p. 2068-2074.

Research output: Contribution to journalArticle

Smith, LH & Teng, NNH 1987, 'Clinical applications of monoclonal antibodies in gynecologic oncology', Cancer, vol. 60, no. 8 SUPPl., pp. 2068-2074.
Smith, Lloyd H ; Teng, N. N H. / Clinical applications of monoclonal antibodies in gynecologic oncology. In: Cancer. 1987 ; Vol. 60, No. 8 SUPPl. pp. 2068-2074.
@article{bb8e793857444575ae024724c1220479,
title = "Clinical applications of monoclonal antibodies in gynecologic oncology",
abstract = "The advances of both murine and human monoclonal antibody (MoAb) technology have allowed the development of several antibodies against gynecologic tumors. The goals are to produce effective and specific reagents for both immunodiagnosis and therapy. However, despite an extensive research effort, a clear demonstration of specific cancer-associated antigens in gynecologic malignancies, or of specific immune responses to such antigens has been elusive. Currently, most antibodies found are cross reactive with either oncofetal antigens or some normal adult tissues. Clinical usefulness of these MoAbs as a screening test in radioimaging or in immunotherapy remains to be proven. However, the use of MoAb technology is defined antigens/tumor markers such as beta-human chorionic gonadotropin, and alpha fetal proteins has provided convenient, reproducible and highly specific reagents. More recently, promising antibodies have been shown to detect tumor antigens in serum of patients with ovarian cancer.",
author = "Smith, {Lloyd H} and Teng, {N. N H}",
year = "1987",
language = "English (US)",
volume = "60",
pages = "2068--2074",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8 SUPPl.",

}

TY - JOUR

T1 - Clinical applications of monoclonal antibodies in gynecologic oncology

AU - Smith, Lloyd H

AU - Teng, N. N H

PY - 1987

Y1 - 1987

N2 - The advances of both murine and human monoclonal antibody (MoAb) technology have allowed the development of several antibodies against gynecologic tumors. The goals are to produce effective and specific reagents for both immunodiagnosis and therapy. However, despite an extensive research effort, a clear demonstration of specific cancer-associated antigens in gynecologic malignancies, or of specific immune responses to such antigens has been elusive. Currently, most antibodies found are cross reactive with either oncofetal antigens or some normal adult tissues. Clinical usefulness of these MoAbs as a screening test in radioimaging or in immunotherapy remains to be proven. However, the use of MoAb technology is defined antigens/tumor markers such as beta-human chorionic gonadotropin, and alpha fetal proteins has provided convenient, reproducible and highly specific reagents. More recently, promising antibodies have been shown to detect tumor antigens in serum of patients with ovarian cancer.

AB - The advances of both murine and human monoclonal antibody (MoAb) technology have allowed the development of several antibodies against gynecologic tumors. The goals are to produce effective and specific reagents for both immunodiagnosis and therapy. However, despite an extensive research effort, a clear demonstration of specific cancer-associated antigens in gynecologic malignancies, or of specific immune responses to such antigens has been elusive. Currently, most antibodies found are cross reactive with either oncofetal antigens or some normal adult tissues. Clinical usefulness of these MoAbs as a screening test in radioimaging or in immunotherapy remains to be proven. However, the use of MoAb technology is defined antigens/tumor markers such as beta-human chorionic gonadotropin, and alpha fetal proteins has provided convenient, reproducible and highly specific reagents. More recently, promising antibodies have been shown to detect tumor antigens in serum of patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023204851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023204851&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 2068

EP - 2074

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8 SUPPl.

ER -